Red Dot
Behold.AI Technologies Limited • Radiology • 02/28/2020
Device Purpose
The red dot™ device is an artificial intelligence-powered software designed to analyze adult chest X-rays for features suggestive of pneumothorax, providing case-level notifications to PACS/workstations for workflow prioritization. Its methodology relies on a visual recognition algorithm processing validated and anonymized DICOM images, with performance studies indicating high diagnostic accuracy (AUROC 0.975, Sensitivity 94.65%) and rapid processing times to aid in the timely triage of potential pneumothorax cases.
Summary
The red dot™ device by Behold.AI Technologies is a software workflow tool designed to assist in the clinical assessment of adult chest X-rays by identifying features suggestive of pneumothorax. It employs an artificial intelligence algorithm, specifically a visual recognition algorithm, to analyze PA/AP chest X-ray images received in DICOM format. The system integrates into the existing radiology workflow by first validating image readability and anonymizing patient identifiable information, then processing them through its AI model. If potential pneumothorax findings are detected, it sends a case-level notification via a standard JSON message to the Picture Archiving and Communication System (PACS) or Radiology Information System (RIS) workstation, enabling prioritization or triage of these cases for earlier review by radiologists; it does not mark images, direct attention to specific locations, or serve as a standalone diagnostic tool. Performance of the red dot™ device was evaluated in a multi-center, retrospective study using 888 anonymized adult chest X-ray images, including 299 pneumothorax positive cases and 589 negative cases, with ground truth established by at least two board-certified radiologists. The study demonstrated strong diagnostic performance for pneumothorax detection, achieving an Area Under the Receiver Operating Characteristic curve (AUROC) of 0.975. The accuracy was 90.20%, with a sensitivity of 94.65% and specificity of 87.95%. The system also exhibited efficient timing, with a mean image processing time of 13.8 seconds and an average notification transit time of 15.5 seconds, resulting in a total red dot™ performance time of approximately 29.3 seconds from image receipt to notification display on the worklist, indicating its potential to expedite the review of critical cases.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the red dot™ algorithm's performance vary with different types and sizes of pneumothoraces (e.g., small apical vs. large tension pneumothorax)?; What specific confounding imaging features were included in the non-normal control group, and how did they impact the algorithm's specificity?; What is the typical range of improvement in radiologist review time for pneumothorax-positive cases when using the red dot™ prioritization system in a real-world clinical setting, beyond the device's processing and notification time?; Beyond the reported AUROC, sensitivity, and specificity, what are the positive and negative predictive values of the red dot™ device given the prevalence of pneumothorax in the study population (299/888 cases)?; How does the image input, validation, and anonymization feature handle images with poor diagnostic quality or corrupted metadata, and are there any failure modes that could prevent an image from being processed or lead to misinterpretation?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly